摘要
目的观察评估在少见实体肿瘤患者治疗中应用阿帕替尼的治疗效果及安全性。方法研究对象抽取医院2016年6月—2020年6月就诊的罹患少见实体瘤患者,根据随机数字表法对48例患者予以分组,对照组选取24例研究对象用最佳支持+化疗方案治疗,观察组选取24例研究对象应用阿帕替尼治疗(单一阿帕替尼治疗或联合其他药物治疗),对两组临床症状缓解率、生活质量以及不良反应发生率所得数值展开对比。结果观察组患者临床症状缓解率、整体生命质量与功能区域评分更高,症状区域评分更低(P<0.05);相较对照组,观察组不良反应发生率更低,但差异无统计学意义(P>0.05)。结论针对临床罹患少见实体瘤患者予以阿帕替尼治疗,患者临床症状缓解良好,生活质量改善效果佳,且患者在治疗期间所出现的不良反应具有良好的耐受性。
Objective To observe and evaluate the efficacy and safety of apatinib in the treatment of rare solid tumors.Methods The study subjects were selected from the hospital from June 2016 to June 2020 with patients with rare solid tumors.48 patients were divided into groups according to the random number table method.The control group was selected 24 subjects who were treated with the best support+chemotherapy regimen for observation.The observation group was selected 24 subjects to be treated with apatinib(apatinib alone or in combination with other drugs),and the clinical symptom relief rate,quality of life and the incidence of adverse reactions were compared between the two groups.Results The clinical symptom remission rate,overall quality of life and functional area score of the observation group were higher,and the symptom area score was lower(P<0.05);compared with the control group,the observation group had a lower incidence of adverse reactions,but the difference was not statistically significant(P>0.05).Conclusion The treatment of apatinib for patients with rare solid tumors in the clinic can relieve the clinical symptoms and improve the quality of life.The adverse reactions during the treatment are well tolerated.
作者
马金国
张冰
MA Jinguo;ZHANG Bing(Department of Internal-oncology,Hulunbuir People’s Hospital,Hulunbuir Inner Mongolia 021008,China;Department of Cardiology,Hulunbuir People’s Hospital,Hulunbuir Inner Mongolia 021008,China)
出处
《中国卫生标准管理》
2021年第19期105-108,共4页
China Health Standard Management
关键词
阿帕替尼
少见实体瘤
临床效果
不良反应
生活质量
临床症状缓解率
apatinib
rare solid tumors
clinical effect
adverse reaction
quality of life
clinical symptom relief rate
